Phosphodiesterase 4 inhibitor, and pharmaceutical composition and application thereof
By synthesizing novel PDE4 inhibitor compounds, the side effects of existing drugs in the treatment of psoriasis and atopic dermatitis have been solved, achieving highly efficient inhibition of PDE4 enzymes and reduction of inflammatory factors, significantly improving disease symptoms and skin sensitivity.
Patent Information
- Application Number
- CN202310569892.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-19
- Publication Date
- 2024-11-22
AI Technical Summary
Existing PDE4 inhibitors have a narrow therapeutic window and persistent side effects when treating psoriasis and atopic dermatitis. There is a need to develop drugs with higher safety profiles to improve intracellular cAMP degradation and reduce the secretion of inflammatory factors.
A new class of phosphodiesterase 4 inhibitor compounds were designed and synthesized. Through specific structural modifications, they inhibited PDE4 activity, increased intracellular cAMP accumulation, and significantly inhibited the secretion of the inflammatory factor TNF-α. These compounds can be applied in pharmaceuticals and cosmetics to treat related diseases and improve skin sensitivity.
The compound significantly inhibits PDE4 enzyme activity, alleviates symptoms of psoriasis and atopic dermatitis, and improves skin sensitivity, demonstrating significant medicinal value and broad application prospects.
Smart Images

Figure CN118994068A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and in particular relates to a phosphodiesterase 4 inhibitor, a pharmaceutical composition thereof and an application thereof. Background Art
[0002] Cyclic nucleotide phosphodiesterases (PDEs) are a super enzyme family that catalyzes the hydrolysis of cAMP and cGMP, and are composed of 21 different genes. Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are two second messengers that play an important role in cell metabolism. PDEs can be divided into 11 different PDE families (PDE1-11) based on their substrate specificity and amino acid sequence. Among them, PDE4 is a highly cAMP-specific phosphodiesterase that contains four subtypes: PDE4A, PDE4B, PDE4C, and PDE4D. Studies have shown that inhibiting PDE4 can improve the degradation of intracellular cAMP, thereby activating PKA and affecting downstream pathways such as CREB / ATF-1 and NF-κB, leading to a decrease in the synthesis of inflammatory cytokines and an increase in anti-inflammatory cytokines. PDE4 is widely distributed in various human tissues and cells, such as the brain, kidney, cardiomyocytes, endothelial cells, and immune cells. Due to its organ specificity, PDE4 is involved in the regulation of cognitive function, promotes the expression of proinflammatory cytokines and chemokines in inflammatory cells (including peripheral blood mononuclear cells, macrophages, neutrophils, natural killer cells, basophils and lymphocytes), and regulates vascular smooth muscle proliferation, vasodilation and cardiac contraction. PDE4A, PDE4B and PDE4D are also involved in the generation of hematological malignancies, central nervous system tumors, breast tumors, lung tumors and prostate tumors. Animal models such as Alzheimer's disease and stroke have confirmed that PDE4 is also a potential target for the treatment of central nervous system diseases. However, due to the narrow therapeutic window and persistent side effects such as nausea, vomiting, diarrhea, etc., the clinical application of PDE4 inhibitors is seriously hindered. Therefore, new PDE4 inhibitors with a larger safety window and better safety are of great significance.
[0003] Psoriasis is a multifactorial, intractable inflammatory skin disease characterized by scaly, red plaques that appear on frequently abraded parts of the body (such as the extensor parts of the limbs and scalp) and are accompanied by multiple comorbidities, which seriously affect the patient's quality of life. The immunopathogenesis of psoriasis involves a variety of inflammatory mediators, including tumor necrosis factor (TNF-α), interleukins (IL-12, IL-17, IL-22, IL-23), and interferon (IFN)-γ. The treatment of psoriasis varies, from topical corticosteroids, retinoids, and calcipotriol, to oral conventional systemic therapy as a broad immunosuppressant, to biological therapies targeting specific cytokines. Among them, topical corticosteroids are the most commonly used, but their long-term side effects, such as skin atrophy and stretch marks, limit their use. In 2022, Zoryve (roflumilast) 0.3% cream was approved for the treatment of localized plaque psoriasis, proving that PDE4 inhibitors have great potential in the treatment of psoriasis. However, Zoryve still has the side effects of roflumilast, such as nausea, diarrhea, loss of appetite, and mild weight loss. Therefore, there is still a clinical need for drugs to treat psoriasis, and providing an efficient and safe drug for the treatment of psoriasis is of great clinical significance.
[0004] Atopic dermatitis is a common allergic skin disease, which is mainly manifested by severe itching of the skin, dryness, erythema, papules and other symptoms, affecting a wide range of people including infants, adolescents and adults. Persistent itching of the skin can cause severe sleep disorders, which not only interferes with daily activities, but also seriously reduces the quality of life, bringing a heavy burden to patients. At present, the first-line treatment option for atopic dermatitis is still steroid anti-inflammatory drugs, such as corticosteroids (such as prednisone, dexamethasone and fludrocortisone). Although these corticosteroids can relieve the symptoms of atopic dermatitis, their long-term use will cause adverse reactions such as skin redness, thinning, atrophy and growth retardation. As a topical anti-inflammatory drug, crisaborole was approved by the FDA in 2016 and was launched in the United States in early 2017 for the treatment of mild to moderate atopic dermatitis in adults and children aged 2 years and above, proving that PDE4 inhibitors have great potential in the treatment of atopic dermatitis.
[0005] Skin sensitivity refers to the skin condition that is susceptible to multiple factors and induces subjective sensory symptoms, that is, the skin is highly reactive, poorly tolerant, and even prone to allergies, such as allergies caused by cosmetic raw materials. Sensitive skin mainly occurs on the face, as well as other parts such as the hands, feet, and scalp. The main characteristics of skin sensitivity are that it is drier than normal skin, prone to tightness and redness; it can produce itching, desquamation, and even burning and stinging sensations when slightly stimulated. Inflammatory response is an important factor in sensitive skin. When the skin is sensitive and uncomfortable, it is more susceptible to external irritants and allergens, resulting in skin inflammation. There is currently no specific treatment for skin sensitivity. PDE4 plays an important role in a variety of skin inflammatory diseases, so it is of great significance to develop PDE4 inhibitors that relieve skin sensitivity. Summary of the invention
[0006] In view of the above problems existing in the prior art, the purpose of the present invention is to provide a compound having PDE4 inhibitory activity and a preparation method and application thereof, so as to screen a new drug and / or cosmetic raw material for preventing and / or treating phosphodiesterase 4-related diseases and skin discomfort.
[0007] In a first aspect of the present invention, there is provided a compound as shown in the following formula I, a stereoisomer, a precursor compound, a deuterated substance, or a pharmaceutically acceptable ester thereof:
[0008]
[0009] In formula I, Z is O, NH or S;
[0010] R1 is selected from H, unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, unsubstituted or halogen-substituted benzyl;
[0011] R2 and R3 are each independently selected from unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, and unsubstituted or halogen-substituted benzyl;
[0012] One of R6 and R7 is H, and the other is in, represents a single bond or a double bond;
[0013] R4 and R5 are each independently selected from
[0014] R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl,
[0015] In the above substituent options Indicates the key connection position,
[0016] Provided that the compound of formula I does not include compound In a specific embodiment, the compound of formula I has the structure shown in the following formula I-1:
[0017]
[0018] In formula I-1, each substituent is as defined above.
[0019] In a specific embodiment, in Formula I,
[0020] Z is O;
[0021] R1 is selected from H, C1-C6 alkyl;
[0022] R2 and R3 are each independently selected from C1 to C6 alkyl;
[0023] R6 is H, and R7 is in, represents a single bond or a double bond;
[0024] R4 and R5 are each independently selected from R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl,
[0025] In the above substituent options Indicates the key connection location.
[0026] In a specific embodiment, in Formula I,
[0027] Z is O;
[0028] R1 is selected from H, C1-C6 alkyl;
[0029] R2 and R3 are each independently selected from C1 to C6 alkyl;
[0030] R6 is and R7 is H, wherein, represents a single bond or a double bond;
[0031] R4 and R5 are each independently selected from R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl,
[0032] In the above substituent options Indicates the key connection location.
[0033] In a specific embodiment, in Formula I,
[0034] Z is O;
[0035] R1 is H or methyl;
[0036] R2 and R3 are both methyl, or R2 and R3 are both ethyl;
[0037] R6 is H, and R7 is in, represents a single bond or a double bond;
[0038] R4 and R5 are each independently selected from
[0039] R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl,
[0040] In the above substituent options Indicates the key connection location.
[0041] In a specific embodiment, in Formula I,
[0042] Z is O;
[0043] R1 is H or methyl;
[0044] R2 and R3 are both methyl, or R2 and R3 are both ethyl;
[0045] R7 is H, and R6 is in, represents a single bond or a double bond;
[0046] R4 and R5 are each independently selected from
[0047] R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl,
[0048] In the above substituent options Indicates the key connection location.
[0049] In another aspect, the present invention provides a compound having the following structure:
[0050]
[0051] In another aspect, the present invention provides a pharmaceutical composition comprising the compound of formula I, a deuterated substance or a pharmaceutically acceptable ester thereof, and a pharmaceutically acceptable excipient.
[0052] In another aspect, the present invention provides the use of a compound of the following formula I, a deuterated substance thereof, or a pharmaceutically acceptable ester thereof, or a pharmaceutical composition comprising the same, in the preparation of a medicament for treating a disease mediated by upregulation of phosphodiesterase 4:
[0053]
[0054] In formula I, Z is O, NH or S;
[0055] R1 is selected from H, unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, unsubstituted or halogen-substituted benzyl;
[0056] R2 and R3 are each independently selected from unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, and unsubstituted or halogen-substituted benzyl;
[0057] One of R6 and R7 is H, and the other is in, represents a single bond or a double bond;
[0058] R4 and R5 are each independently selected from Wherein, R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, R 10 It is a C1~C6 alkyl group.
[0059] In the above substituent options Indicates the key connection location.
[0060] In a specific embodiment, the present invention provides the use of the following compound or a pharmaceutical composition comprising the same in the preparation of a medicament for treating a disease mediated by upregulation of phosphodiesterase 4, a PDE4 inhibitor, or a cosmetic for improving skin sensitivity:
[0061]
[0062] In a specific embodiment, the diseases include: diseases involving inflammation, such as asthma, COPD and pulmonary fibrosis, allergic disease states, such as atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, chronic glomerulonephritis, endotoxic shock, cystic fibrosis, arterial restenosis, atherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, diabetes, pneumoconiosis, toxic and allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, pruritus of the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular and generalized pyoderma, endogenous or exogenous acne, erythematosus Acne, Beghet's disease, Henoch-Schonlein purpura nephritis, inflammatory bowel disease, leukemia, multiple sclerosis, gastrointestinal diseases, autoimmune diseases, etc.; cardiovascular diseases, such as arrhythmia, heart failure, idiopathic dilated cardiomyopathy, acute myocardial infarction, myocardial ischemia-reperfusion injury, ischemic pulmonary hypertension; neurological and mental disorders, such as Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, depression, stroke, as well as spinal cord injury, vascular dementia, fragile X syndrome; malignant tumors include central nervous system tumors, malignant blood diseases, lung cancer, liver cancer, oral cancer, breast cancer, colon cancer, stomach cancer, skin cancer, prostate cancer, head and neck cancer, bladder cancer and pancreatic cancer.
[0063] In specific embodiments, the disease is psoriasis or atopic dermatitis.
[0064] In another aspect, the present invention provides a cosmetic comprising at least the compound of formula I, its deuterated product, or pharmaceutically acceptable ester as an active ingredient for improving skin sensitivity.
[0065] In a specific embodiment, the form of the cosmetic is not limited, and can be emulsion, oil, cream, etc.
[0066] In another aspect, the present invention provides a method for treating a phosphodiesterase 4-mediated disease in a subject, the method comprising administering to the subject a therapeutically effective amount of the compound of formula I, a deuterated substance thereof, or a pharmaceutically acceptable ester thereof.
[0067] In another aspect, the present invention provides a method for treating psoriasis or atopic dermatitis in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula I, a deuterated substance thereof, or a pharmaceutically acceptable ester thereof, or administering a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula I, a deuterated substance thereof, or a pharmaceutically acceptable ester thereof.
[0068] Beneficial Effects
[0069] The compound of formula I of the present application can effectively inhibit the activity of phosphodiesterase 4, increase the accumulation of intracellular cAMP, and significantly inhibit the secretion of inflammatory factor TNF-α in human peripheral blood mononuclear cells. Therefore, the compound of formula I is expected to be used as an active ingredient for the preparation of drugs for preventing and / or treating phosphodiesterase 4-related diseases, and is particularly expected to be used for the preparation of drugs for preventing and / or treating psoriasis and atopic dermatitis, and therefore has significant medicinal value and broad application prospects.
[0070] The general compound of the present application can also effectively improve skin sensitivity, and thus can be used to prepare cosmetics for improving skin sensitivity. BRIEF DESCRIPTION OF THE DRAWINGS
[0071] Figure 1 The inhibition curve of compound 7b-1 in Test Example 1 on the catalytic domain of PDE4D is shown.
[0072] Figure 2 The inhibition curve of compound 7b-1 in Test Example 2 on the secretion of inflammatory factor TNF-α in human PBMC cells is shown.
[0073] Figure 3 The therapeutic effect of compound 7b-1 on imiquimod-stimulated psoriasis in mice in Test Example 3 is shown. (A) Imiquimod-stimulated psoriasis lesion area and total score of severity index in mice; (B) erythema score in mouse back lesions; (C) scale score in mouse back lesions; (D) thickness score in mouse back lesions. Compared with the blank group, #P<0.05, ##P<0.01, ###P<0.001; compared with the drug matrix group, *P<0.05, **P<0.01 and ***P<0.001.
[0074] Figure 4 The therapeutic effect of compound 7b-1 on atopic dermatitis in mice stimulated by 2,4-dinitrochlorobenzene (DNCB) in Test Example 4 is shown. (A) Scores of skin lesions on the back of mice in DNCB-induced skin allergic reactions; (B) Scores of scales in skin lesions on the back of mice; (C) Scores of epidermal exfoliation in skin lesions on the back of mice; (D) Scores of erythema in skin lesions on the back of mice; (compared with the blank group, #P<0.05, ##P<0.01, ###P<0.001; compared with the model group, *P<0.05, **P<0.01 and ***P<0.001). DETAILED DESCRIPTION
[0075] Hereinafter, the technical solution of the present application is described in detail through specific embodiments so that those skilled in the art can better understand the present invention. However, the protection scope of the present invention is not limited thereto, but includes all equivalent or alternative methods that can be made by those skilled in the art based on the understanding of the present invention.
[0076] the term
[0077] The term "C1-C6 alkyl" includes methyl, ethyl, propyl, butyl, pentyl and hexyl, preferably methyl or ethyl.
[0078] The term "C3-C6 cycloalkyl" refers to cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0079] The term "compound having PDE4 inhibitory activity" refers to a compound capable of inhibiting phosphodiesterase 4 and its isoforms.
[0080] The term "pharmaceutically acceptable" means that the substance does not have such properties that, taking into account the disease or condition to be treated and the respective route of administration, this property will cause a rational and prudent medical practitioner to avoid administering the substance to a patient. For example, for injectables, it is generally required that such a substance is substantially sterile.
[0081] The term "stereoisomer" refers to isomers resulting from different spatial arrangements of atoms in a molecule, including conformational isomers, optical isomers, and the like.
[0082] The term "precursor compound" refers to a compound that is inactive in vitro but can be converted into the active ingredient of the present invention by metabolism or chemical reaction in vivo, thereby exerting its pharmacological effect.
[0083] The drug of the present invention can be administered to patients by various routes of administration, including but not limited to oral, transdermal, intramuscular, subcutaneous and intravenous injection.
[0084] The dosage form of the drug of the present invention is not limited, as long as it is a dosage form that can effectively enable the active ingredients to reach the body, including: tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, capsules, hard capsules, soft capsules, oral liquids, lozenges, granules, granules, pills, powders, pastes, pills, suspensions, powders, solutions, injections, suppositories, ointments, plasters, creams, sprays, drops, patches, etc.; oral dosage forms are preferred, such as: capsules, tablets, oral liquids, granules, pills, powders, pills, pastes, etc.
[0085] In addition to the main active ingredients, the medicine and / or cosmetics of the present invention may also contain a small amount of secondary ingredients that do not affect the active ingredients and / or pharmaceutically acceptable carriers and various necessary excipients for preparations. For example, when the medicine is an oral dosage form, it may contain commonly used excipients such as adhesives, fillers, diluents, compressed tablets, lubricants, disintegrants, colorants, flavoring agents and wetting agents, and the tablets may be coated if necessary. Suitable fillers include cellulose, mannitol, lactose and other similar fillers; suitable disintegrants include starch, polyvinyl pyrrolidone and starch derivatives, such as sodium starch glycolate; suitable lubricants include, for example, magnesium stearate; suitable pharmaceutically acceptable wetting agents include sodium lauryl sulfate.
[0086] The present invention also contemplates the use of pharmaceutically acceptable deuterated compounds or other non-radioactive substituted compounds of the compound. Deuteration is the replacement of one or more or all hydrogens in the active molecular group of the drug with the isotope deuterium, which is considered to be an excellent modification method because it is non-toxic and non-radioactive, and is about 6 to 9 times more stable than carbon-hydrogen bonds. It can block metabolic sites and prolong the half-life of the drug, thereby reducing the therapeutic dose without affecting the pharmacological activity of the drug.
[0087] The term "ester" as used herein refers to a compound of Formula I of the present invention, wherein the hydroxyl group (if present) has been converted to the corresponding ester using, for example, an inorganic or organic anhydride, acid or acid chloride. The term "pharmaceutically acceptable ester" refers to an ester of a compound of Formula I described herein that is pharmacologically acceptable and substantially nontoxic to the subject to which it is administered. More specifically, these esters retain the biological effectiveness and properties of the compounds of Formula I described herein, and act as prodrugs that, when administered in vivo, are metabolized or cleaved in a manner that produces the parent compound.
[0088] Examples of esters include, inter alia, the following groups: (1) carboxylates; (2) sulfonates, such as alkyl- or arylalkyl-sulfonates (e.g. methanesulfonate); (3) phosphonates; (4) monophosphates, diphosphates or triphosphates (including phosphoramidates); (5) carbamates (e.g. N-methylcarbamate); (6) carbonates obtained by esterification of a hydroxyl group (e.g. methyl carbonate), the ester group including, for example, a straight-chain or branched alkyl group (e.g. ethyl, n-propyl, tert-butyl, n-butyl, methyl, propyl, isopropyl, butyl, isobutyl or pentyl), an alkoxyalkyl group (e.g. methoxymethyl, acetoxymethyl and 2,2-dimethylpropionyloxymethyl), an aralkyl group (e.g. benzyl), an aryloxyalkyl group (e.g. phenoxymethyl), an aryl group (e.g. phenyl optionally substituted by, for example, halogen, C1-4 alkyl or C1-4 alkoxy or amino).
[0089] The compounds of formula I described herein can be esterified by various conventional methods, including reacting appropriate anhydrides, carboxylic acids or acyl chlorides with alcohol groups of the compounds described herein. For example, appropriate anhydrides can react with alcohols in the presence of a base such as 1,8-bis[dimethylamino]naphthalene or N,N-dimethylaminopyridine to promote acylation. In addition, suitable carboxylic acids can react with alcohols in the presence of dehydrating agents such as dicyclohexylcarbodiimide, 1-[3-dimethylaminopropyl]-3-ethylcarbodiimide or other water-soluble dehydrating agents for driving the reaction by removing water and optional acylation catalysts. Esterification can also be carried out using appropriate carboxylic acids. The reaction of acyl chlorides with alcohols can also be carried out. When the compounds described herein contain many free hydroxyl groups, those groups that are not converted into prodrug functional groups can be protected (for example, using tert-butyl-dimethylsilyl) and then deprotected. Moreover, enzymatic methods can be used to selectively phosphorylate or dephosphorylate alcohol functional groups. Those skilled in the art will readily know how to successfully implement these and other known alcohol esterification methods.
[0090] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments.
[0091] The preparation process of each specific compound in the following examples is shown in the following reaction flow:
[0092]
[0093]
[0094] In the above reaction formula, R1 is methyl or ethyl.
[0095] Example 1: Preparation of Compound 7a
[0096]
[0097] Preparation of intermediate 2a: Add 1a (10 g, 60.24 mmol) and malonic acid (8.77 g, 84.34 mmol) to a reaction flask, add toluene (180 mL) to dissolve, add pyridine (36 mL) and piperidine (6 mL) respectively and install a water separator, reflux (110 ° C) for 6 hours, a large amount of white solid precipitates, and the reaction is terminated. Filter the reaction system to obtain an off-white solid compound 2b (13.38 g), which is directly used in the next step.
[0098]
[0099] Preparation of intermediate 3a: 2a (15 g, 77.3 mmol) was dissolved in anhydrous methanol (150 mL), concentrated sulfuric acid (4.5 mL) was slowly added dropwise, and the reaction was terminated after stirring at reflux (70°C) for 4 hours. Ethyl acetate (400 mL) and water (100 mL) were added to dilute the reaction solution, extracted with ethyl acetate, and the organic phase was washed with saturated sodium bicarbonate and saturated sodium chloride, combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a yellow oil (15.1 g), which was used for the next step.
[0100]
[0101] Preparation of compound 4a: Anhydrous dichloromethane (150 mL) was added to the reaction bottle containing compound 3a. After sufficient dissolution, silver oxide (8.92 g, 38.5 mmol) was added. Nitrogen was protected, and the bottle was wrapped with aluminum foil. After stirring at room temperature for 24 hours, the reaction was terminated. The reaction solution was filtered with diatomaceous earth, concentrated, and separated by column chromatography to obtain a white solid compound 4a (4.4 g, two-step yield was 28%).
[0102]
[0103] The nuclear magnetic resonance hydrogen spectrum data of 4a tested are as follows:
[0104] 1 H NMR(500MHz,DMSO-d6)δ9.16(s,1H),7.63(d,J=15.9Hz,1H),7.38(s,1H),7.28(s,1H),7.00(d,J=2.0Hz,1H),6.81(dd,J=8.2,2.0Hz,1H),6. 76(d,J=8.0Hz,1H),6.56(d,J=15.9Hz,1H),5.91(d,J=7.8Hz,1H),4.54(d,J=7.8Hz,1H),3.84(s,3H),3.76(s,3H),3.75(s,3H),3.72(s,3H).
[0105] Preparation of compound 5a: Compound 4a (4.3 g, 10.4 mmol) was added to a reaction flask, and anhydrous acetone (100 mL) was added to dissolve the solid. Potassium carbonate (14.4 g, 104.3 mmol) and dimethyl sulfate (9.89 mL, 104.3 mmol) were added, and the reaction was terminated after stirring at reflux (60 ° C for 4 h). Methanol (20 mL) was added to the reaction solution, and a large amount of white solid precipitated after ultrasonic treatment. The mixture was transferred to a refrigerator overnight and filtered to obtain white solid compound 5a (2.7 g, yield 61%).
[0106]
[0107] The H NMR spectrum data of 5a are as follows:
[0108] 1 H NMR (500MHz, DMSO-d6) δ7.63(d,J=16.0Hz,1H),7.39(d,J=1.5Hz,1H),7.28(t,J=1.3Hz,1H),7.03(d,J=1.8Hz,1H),6. 94(m,2H),6.56(d,J=15.9Hz,1H),5.96(d,J=7.8Hz,1H),4.55(d,J=7.8Hz,1H),3.85(s,3H),3.75(m,9H),3.71(s,3H).
[0109] Preparation of compound 6a: Add 5a (2 g, 4.67 mmol) to a reaction flask, dissolve it in ethyl acetate (25 mL), add palladium carbon (200 mg, 10 wt%), introduce hydrogen, and react at room temperature for 3 h before the reaction is terminated. The reaction solution is filtered with diatomaceous earth and concentrated to obtain a light yellow oil compound 6a, which is used for the next step.
[0110]
[0111] The nuclear magnetic resonance hydrogen spectrum data of 6a tested are as follows:
[0112] 1 H NMR (500MHz, DMSO-d6) δ7.02(d,J=2.0Hz,1H),6.95(d,J=8.3Hz,1H),6.92(dd,J=8.3,1.9Hz,1H),6.85(d,J=1.6Hz,1H),6.76(t,J= 1.3Hz,1H),5.87(d,J=8.1Hz,1H),4.46(d,J=8.0Hz,1H),3.78(s,3H),3.75(m,9H),3.60(s,3H),2.81(t,J=7.6Hz,2H),2.65(m,2H).
[0113] Preparation of compound 7a: Add lithium aluminum tetrahydride (1.57 g, 41.4 mmol) to a three-necked flask that has been dried, protect with nitrogen and place in an ice bath, add anhydrous tetrahydrofuran (20 mL) to dissolve. Dissolve compound 6a in anhydrous tetrahydrofuran (20 mL) and slowly add to the reaction system. React at room temperature for 2 h before the reaction is terminated. Slowly drop water (1.57 mL) under ice bath conditions to quench the reaction, adjust the pH to acidic with 1M HCl, extract with ethyl acetate, wash the organic phase with saturated sodium bicarbonate and saturated sodium chloride, combine the organic phases, dry the organic phase with anhydrous sodium sulfate, filter, concentrate, and separate by column chromatography to obtain a colorless oil compound 7a (1.1 g, two-step yield is 63%).
[0114]
[0115] The nuclear magnetic resonance hydrogen spectrum data of 7a tested are as follows:
[0116] 1 H NMR (500MHz, DMSO-d6) δ6.94(d,J=8.9Hz,2H),6.89(d,J=8.2Hz,1H),6.70(s,2H),5.78(s,0H),5.46(d,J=6.7Hz,1H),5.04(t,J= 5.3Hz, 1H), 4.47 (t, J = 5.1Hz, 1H), 3.78 (s, 3H), 3.74 (d, J = 2.9Hz, 6H), 3.63 (m, 2H), 3.42 (q, J = 6.1Hz, 3H), 1.70 (p, J = 7.1Hz, 2H).
[0117] Example 2: Preparation of Compounds 7a-1 and 7a-2
[0118] Preparation of compounds 7a-1 and 7a-2: Compound 7a was injected into a DAICEL CHIRALPAK AD-H column, using petroleum ether-ethanol (80:20) as the mobile phase, a flow rate of 0.8 mL / min, a column temperature of 25°C, and an ultraviolet detection wavelength of 210 nm to obtain enantiomers 7a-1 (450 mg, purity: 99.2%) and 7a-2 (510 mg, purity: 99.8%).
[0119]
[0120] Example 3: Preparation of Compound 9a
[0121] Preparation of compound 8a: In a round-bottom flask containing compound 5a (400 mg, 0.93 mmol), lithium hydroxide monohydrate (153 mg, 3.74 mmol) dissolved in tetrahydrofuran: methanol: water (4:2:2 mL) was added, and the reaction was terminated after reacting at room temperature for 4 hours. The reaction solution was concentrated, 1M HCl was added to adjust the pH to acidic, extracted with ethyl acetate, the organic phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain a white solid 8a (251 mg, 68%).
[0122]
[0123] The nuclear magnetic resonance hydrogen spectrum data of 8a tested are as follows:
[0124] 1H NMR(500MHz,DMSO-d6)δ12.69(s,2H),7.55(d,J=15.8Hz,1H),7.34(s,1H),7.24(s,1H),7.01(s,1H),6.93(q, J=8.4Hz,2H),6.42(d,J=15.8Hz,1H),5.94(d,J=7.6Hz,1H),4.41(d,J=7.6Hz,1H),3.84(s,3H),3.74(s,6H).
[0125] Preparation of compound 9a: To a round-bottom flask containing 8a (230 mg, 0.58 mmol), dioxane (5 mL) was added to dissolve the reactant, and di-tert-butyl dicarbonate (0.396 mL, 1.73 mmol), pyridine (0.138 mL, 1.73 mmol), and ammonium bicarbonate (136 mg, 1.73 mmol) were added respectively. The reaction was terminated after stirring at room temperature overnight.
[0126] The reaction solution was concentrated and purified by column chromatography to obtain white solid compound 9a (133 mg, 58%).
[0127]
[0128] The tested H NMR spectrum data of 9a are as follows:
[0129] 1 H NMR (500MHz, DMSO-d6) δ7.82(d,J=2.4Hz,1H),7.44(s,1H),7.37(m,2H),7.14(d,J=1.7Hz,1H),7.09(s,1H),6.98(m,2H),6.93(d,J=2.0Hz ,1H),6.87(dd,J=8.3,2.0Hz,1H),6.47(d,J=15.8Hz,1H),5.95(d,J=7.9Hz,1H),4.23(d,J=7.9Hz,1H),3.84(s,3H),3.75(d,J=3.6Hz,6H).
[0130] Example 4: Preparation of Compound 10a
[0131] Preparation of compound 10a: Add compound 7a (100 mg, 0.27 mmol) to a reaction flask and dissolve it with dichloromethane. Add triethylamine (167 μL, 1.20 mmol) and methanesulfonyl chloride (50 μL, 0.64 mmol) under ice bath, protect with nitrogen, and react at room temperature for 2 hours to complete the reaction. The reaction solution was adjusted to acidic pH with 1M HCl, extracted with dichloromethane three times, washed with saturated sodium chloride, dried with anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain compound 10a (82 mg, 63%)
[0132]
[0133] The nuclear magnetic resonance hydrogen spectrum data of 10a tested are as follows:
[0134] 1 H NMR (500MHz, DMSO-d6) δ6.97(m,2H),6.90(d,J=8.3Hz,1H),6.81(s,2H),5.51(d,J=7.1Hz,1H),4.53(dd,J=10.2,4.9Hz,1H),4.47(dd,J=10.2 ,6.9Hz,1H),4.20(t,J=6.2Hz,2H),3.79(s,3H),3.74(d,J=3.0Hz,6H),3.20(s,3H),3.18(s,3H),2.62(t,J=7.7Hz,2H),1.96(p,J=6.7Hz,2H).
[0135] Example 5: Preparation of Compound 11a
[0136] Add trichloroacetyl isocyanate (22.6 mg, 0.12 mmol) to dichloromethane (3 mL) containing compound 7a (20 mg, 0.05 mmol) and place in an ice bath. After 3 hours, TLC indicates that the reaction of the raw material is complete. After concentration, dissolve in methanol (3 mL), add anhydrous potassium carbonate (1.38 mg, 0.01 mmol) and stir overnight. Post-treatment: Concentrate the reaction solution, extract with dichloromethane and water, wash with saturated ammonium chloride, wash with saturated sodium chloride, dry with anhydrous sodium sulfate, filter, and separate with column chromatography to obtain compound 11-a (9 mg, 39%).
[0137] The nuclear magnetic resonance hydrogen spectrum data of 11a tested are as follows:
[0138] 1H NMR (400MHz, DMSO-d6) δ6.91(m,3H),6.74(s,2H),6.47(s,4H),5.42(d,J=7.2Hz,1H),4.19(p,J=10.2,9. 1Hz,2H),3.97(m,3H),3.78(s,3H),3.74(s,6H),3.68-3.57(m,1H),2.67-2.53(m,3H),1.90-1.74(m,2H).
[0139]
[0140] Example 6: Preparation of Compound 12a
[0141] Preparation of compound 12a: 8a (50 mg, 0.125 mmol) and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazole-1-yl) urea hexafluorophosphate (104.5 mg, 0.215 mmol) were added to a reaction flask and dissolved with dichloromethane; dimethylamine (17.2 μL, 0.25 mmol), triethylamine (69.3 μL, 0.5 mmol) and N,N-dimethylformamide (2 drops) were added, nitrogen was protected, and the reaction was terminated after 3 hours at room temperature. The reaction solution was added with 1M HCl to adjust the pH to acidic, extracted with dichloromethane, and the organic phase was washed with water three times, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and separated by column chromatography to obtain an off-white solid 12a (37 mg, 65%).
[0142]
[0143] The nuclear magnetic resonance hydrogen spectrum data of 12a tested are as follows:
[0144] 1 H NMR (500MHz, DMSO-d6) δ7.45(d,J=15.3Hz,1H),7.34(s,1H),7.06(m,3H),6.94(t,J=6.5Hz,2H),5.93(d,J=8 .5Hz,1H),4.89(d,J=8.5Hz,1H),3.85(s,3H),3.75(s,5H),3.16(s,3H),3.12(s,3H),2.92(d,J=4.1Hz,6H).
[0145] Example 7: Preparation of Compound 7b
[0146]
[0147] Preparation of compound 2b: The method is the same as that of 2a.
[0148]
[0149] Preparation of compound 3b: The method was the same as that of 3a. After cooling, the product was recrystallized to obtain an off-white solid compound 3b (9.2 g, two-step yield 69%).
[0150]
[0151] The nuclear magnetic resonance hydrogen spectrum data of 3b tested are as follows:
[0152] 1 H NMR(500MHz,DMSO-d6)δ9.52(s,1H),7.55(d,J=15.9Hz,1H),7.29(d,J=2.0Hz,1H),7.11(dd,J=8.2,2.0Hz,1 H), 6.81 (d, J = 8.2Hz, 1H), 6.45 (d, J = 15.9Hz, 1H), 4.07 (q, J = 7.0Hz, 2H), 3.69 (s, 3H), 1.33 (t, J = 7.0Hz, 3H).
[0153] Preparation of compound 4b: The method was the same as that of compound 4a to obtain off-white solid compound 4b (2.03 g, 23%).
[0154]
[0155] The nuclear magnetic resonance hydrogen spectrum data of 4b tested are as follows:
[0156] 1 H NMR(500MHz,DMSO-d6)δ9.12(s,1H),7.63(d,J=15.9Hz,1H),7.33(m,2H),7.00(d,J=2.0Hz,1H),6.82(m,2H),6.56(d,J=16.0Hz,1H),5 .90(d,J=7.8Hz,1H),4.55(d,J=7.8Hz,1H),4.13(qd,J=7.0,4.6Hz,2H),4.01(m,2H),3.75(s,3H),3.72(s,3H),1.32(t,J=6.9Hz,6H).
[0157] Preparation of compound 5b: The method was the same as that of compound 5a to obtain white solid compound 5b (165 mg, 82%).
[0158]
[0159] The nuclear magnetic resonance hydrogen spectrum data of 5b tested are as follows:
[0160] 1H NMR (500MHz, DMSO-d6) δ7.62(d,J=15.9Hz,1H),7.37(s,1H),7.27(s,1H),7.02(s,1H),6.95(t,J=6.1Hz,2H),6.55(d,J=15.9Hz,1 H),5.93(d,J=7.8Hz,1H),4.54(d,J=7.8Hz,1H),4.15(m,J=7.3,6.6Hz,2H),3.99(m,2H),3.74(m,9H),1.30(td,J=6.9,4.0Hz,6H).
[0161] Preparation of compound 6b: The method was the same as that of compound 6a to obtain off-white solid compound 6b (127 mg, 82%).
[0162]
[0163] The nuclear magnetic resonance hydrogen spectrum data of 6b tested are as follows:
[0164] 1 H NMR (500MHz, DMSO-d6) δ6.99(d,J=1.9Hz,1H),6.93(m,2H),6.81(d,J=1.8Hz,1H),6.74(s,1H),5.83(d,J=8.1Hz,1H),4.43(d,J=8.1Hz, 1H),4.02(m,3H),3.75(s,3H),3.72(s,3H),3.58(s,3H),2.78(t,J=7.6Hz,2H),2.60(td,J=8.0,7.6,4.9Hz,2H),1.29(q,J=6.9Hz,6H).
[0165] Preparation of compound 7b: The method was the same as that of compound 7a to obtain compound 7b (97 mg, 95%) as a light yellow oil.
[0166]
[0167] The nuclear magnetic resonance hydrogen spectrum data of 7b tested are as follows:
[0168] 1H NMR(500MHz,DMSO-d6)δ6.93(dd,J=5.2,3.1Hz,2H),6.87(dd,J=8.3,2.0Hz,1H),6.67(d,J=7 .7Hz,2H),5.76(s,1H),5.43(d,J=6.7Hz,1H),5.01(t,J=5.3Hz,1H),4.44(t,J=5.1Hz,1H),4. 13-3.93(m,4H),3.74(s,3H),3.69(dt,J=10.6,5.3Hz,1H),3.60(dt,J=10.7,6.4Hz,1H),3.4 0(p,J=5.7Hz,3H),2.52(d,J=8.5Hz,2H),1.68(dq,J=13.2,6.8Hz,2H),1.30(q,J=6.7Hz,6H).
[0169] Example 8: Preparation of Compounds 7b-1 and 7b-2
[0170] Preparation of compounds 7b-1 and 7b-2: The method is the same as that of compounds 7a-1 and 7a-2 to obtain enantiomers 7b-1 (1 g, purity: 96%) and 7b-2 (0.94 g, purity: 99%)
[0171]
[0172] Example 9: Preparation of Compound 9b
[0173] Preparation of compound 8b: The method was the same as that of 8a to obtain white solid compound 8b (222 mg, 61%).
[0174]
[0175] The nuclear magnetic resonance hydrogen spectrum data of 8b tested are as follows:
[0176] 1H NMR (500MHz, DMSO-d6) δ12.69(s,2H),7.56(d,J=15.9Hz,1H),7.33(d,J=1.7Hz,1H),7.2 5(d,J=1.3Hz,1H),7.02(d,J=1.9Hz,1H),6.97(d,J=8.4Hz,1H),6.94(dd,J=8.3,1.9Hz,1 H),6.42(d,J=15.9Hz,1H),5.94(d,J=7.7Hz,1H),4.41(d,J=7.6Hz,1H),4.14(qd,J=7.0, 4.5Hz, 2H), 4.01 (dtt, J=16.5, 9.6, 7.0Hz, 2H), 3.77 (s, 3H), 1.32 (td, J=7.0, 5.2Hz, 6H).
[0177] Preparation of compound 9b: The method was the same as that of 9a to obtain an off-white compound 9b (20 mg, 40%).
[0178]
[0179] The nuclear magnetic resonance hydrogen spectrum data of 9b tested are as follows:
[0180] 1 H NMR(500MHz,DMSO-d6)δ7.82(d,J=2.5Hz,1H),7.44(s,1H),7.35(m,2H),7.12(d,J=1.6 Hz,1H),7.08(s,1H),7.00(s,1H),6.97(d,J=8.3Hz,1H),6.92(d,J=2.0Hz,1H),6.87(dd ,J=8.3,2.0Hz,1H),6.46(d,J=15.7Hz,1H),5.92(d,J=7.9Hz,1H),4.22(d,J=7.9Hz,1H) ,4.11(qd,J=6.9,4.7Hz,2H),3.99(q,J=7.0Hz,2H),3.75(s,3H),1.31(q,J=6.8Hz,7H).
[0181] Example 10: Preparation of Compound 10b
[0182] Preparation of compound 10b: The method was the same as that of compound 10a to obtain compound 10b (37 mg, 53%) as a light yellow oil.
[0183]
[0184] The nuclear magnetic resonance hydrogen spectrum data of 10b tested are as follows:
[0185] 1 H NMR (500MHz, DMSO-d6) δ6.97(m,2H),6.90(dd,J=8.3,2.0Hz,1H),6.82-6.76(m,2H),5.49(d,J=7. 0Hz,1H),4.52(dd,J=10.1,4.9Hz,1H),4.46(dd,J=10.1,7.0Hz,1H),4.20(t,J=6.3Hz,2H),4.07(d ddd,J=16.7,9.8,7.0,2.7Hz,2H),3.99(qd,J=6.9,1.8Hz,2H),3.80(q,J=6.5Hz,1H),3.31(s,10H ),3.19(s,3H),3.17(s,3H),2.61(dd,J=8.9,6.5Hz,2H),1.95(m,2H),1.30(td,J=7.0,3.5Hz,6H).
[0186] Example 11: Preparation of Compound 12b
[0187] Preparation of compound 12b: The method was the same as that of compound 12a to obtain off-white solid compound 12b (46 mg, 40%).
[0188]
[0189] The nuclear magnetic resonance hydrogen spectrum data of 12b tested are as follows:
[0190] 1 H NMR (500MHz, DMSO-d6) δ7.43(d,J=15.2Hz,1H),7.32(d,J=1.5Hz,1H),7.04(m,3H),6.94(m,2H),5.90(d,J=8.4Hz,1H),4.88(d ,J=8.5Hz,1H),4.15(m,2H),4.00(m,2H),3.75(s,3H),3.16(s,3H),3.11(s,3H),2.91(d,J=6.0Hz,6H),1.31(q,J=6.8Hz,7H).
[0191] Example 12: Preparation of Compound 16
[0192]
[0193] Preparation of compound 13: Add salvianolic acid B (purity 60%, 10 g, 13.9 mmol) to a reaction flask, add anhydrous acetone (150 mL) to dissolve, then add potassium carbonate (38.4 g, 278 mmol) and dimethyl sulfate (39.5 mL, 417 mmol) in sequence, reflux (60°C) for 5 hours and then terminate the reaction. The reaction solution was filtered with diatomaceous earth, concentrated, and separated by column chromatography to obtain yellow solid compound 13 (2.52 g, 36%).
[0194]
[0195] The nuclear magnetic resonance hydrogen spectrum data of 13 tested are as follows:
[0196] 1 H NMR (500MHz, DMSO-d6) δ7.55(d,J=15.9Hz,1H),7.42(d,J=8.6Hz,1H),7.07(d,J=8 .6Hz,1H),6.93(m,2H),6.82(m,4H),6.71(d,J=8.2Hz,1H),6.66(d,J=2.0Hz,1H), 6.51(dd,J=8.2,2.0Hz,1H),6.41(d,J=15.9Hz,1H),5.84(d,J=5.6Hz,1H),5.22(m ,2H),4.70(d,J=5.6Hz,1H),3.88(s,3H),3.73(m,15H),3.60(m,9H),3.01(m,3H).
[0197] Preparation of intermediate 14: Compound 13 (2.5 g, 2.96 mmol) was added to the reaction flask, and after dissolving in dichloromethane (30 mL), sodium methoxide (0.64 g, 11.84 mmol, dissolved in 19.7 mL methanol to prepare 0.6 N) was slowly added dropwise under ice bath, and stirred at room temperature for 2.5 h. TLC detected that the raw material reaction was complete. 1 M HCl was added under ice bath conditions to adjust the pH to acidic, and ethyl acetate was used for extraction. The organic phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain yellow oily compound 14 (0.9 g, 71%).
[0198]
[0199] The nuclear magnetic resonance hydrogen spectrum data of 14 tested are as follows:
[0200] 1H NMR (500MHz, DMSO-d6) δ7.62(d,J=15.9Hz,1H),7.42(d,J=8.5Hz,1H),7.04(m,2H),6.92(m,3H),6.46(d,J=15.9Hz, 1H),5.95(d,J=5.7Hz,1H),4.75(d,J=5.7Hz,1H),3.87(s,3H),3.76(s,3H),3.75(s,4H),3.71(s,3H),3.70(s,3H).
[0201] Preparation of compound 15: The method was the same as that of 6a to obtain compound 15 (136 mg, 71%) as a pale yellow oil.
[0202]
[0203] The nuclear magnetic resonance hydrogen spectrum data of 15 tested are as follows:
[0204] 1 HNMR(500MHz,DMSO-d6)δ6.93(ddd,J=33.5,16.6,10.1Hz,4H),6.73(d,J=8.3Hz,1H),5.86(d, J=5.8Hz,1H),4.48(d,J=5.8Hz,1H),3.76(dt,J=19.0,15.5Hz,14H),3.55(s,3H),2.69(m,2H).
[0205] Preparation of compound 16: The method was the same as that of compound 7a to obtain compound 16 (60 mg, 51%) as a light yellow oil.
[0206]
[0207] The nuclear magnetic resonance hydrogen spectrum data of 16 tested are as follows:
[0208] 1 H NMR (500MHz, DMSO-d6) δ6.90(d,J=8.3Hz,1H),6.85(d,J=2.0Hz,1H),6.79(td,J=5.5,2.8Hz,2H),6.62(d,J=8.3Hz,1H),5.64(d,J=2.8Hz, 1H),5.13(t,J=5.2Hz,2H),4.45(t,J=5.1Hz,1H),3.75(s,4H),3.71(s,3H),3.70(s,3H),3.42(m,4H),2.51(m,9H),1.64(p,J=6.9Hz,2H).
[0209] Example 13: Preparation of Compound 18
[0210] Preparation of compound 17: The method is the same as that of compound 8a, and the crude product is directly used in the next step.
[0211]
[0212] Preparation of compound 18: The method was the same as that of compound 9a to obtain off-white solid compound 18 (27 mg, two-step yield 27%).
[0213]
[0214] Preparation Example 1: Preparation of Compound 7b Lotion
[0215] The components of phase AD are shown in Table 1 below, and a lotion is prepared as follows.
[0216] 1) Pre-disperse sodium hyaluronate evenly, add other raw materials in phase A, stir evenly, and heat to 80-85°C.
[0217] 2) Add all ingredients of phase B and raise the temperature to 80-85°C. Add phase B to phase A (stirring) and homogenize at medium-high speed (10000-12000 rpm) for 5 minutes.
[0218] 3) Cool down to 50°C, add phase C, and homogenize at medium-low speed (7000-8000 rpm) for 3 min.
[0219] 4) Cool down to 45°C and add phase D. The solid powder needs to be pre-dissolved.
[0220] 5) Stop.
[0221] Table 1 Component formula of lotion
[0222]
[0223]
[0224] Preparation Example 2: A lotion was prepared in the same manner as in Preparation Example 1, except that the raw materials of the lotion were composed as follows (by weight percentage): 0.05% disodium EDTA, 2% glycerin, 0.5% panthenol, 2% butylene glycol, 0.03% hyaluronic acid, 0.01% sodium hyaluronate, 2% EMULIUM MELLIFERA raw material, 2% squalane, 2% caprylic / capric triglyceride, 2% dimethicone, 1% compound 7b, 0.9% Simulgel 305 raw material, 0.8% SPECTRASTARPHL raw material, 1% NACARE Cerasome III (ceramide), 6% raw material, and the balance was water.
[0225] Preparation Example 3: A lotion was prepared in the same manner as in Preparation Example 1, except that the raw materials of the lotion were composed as follows (by weight percentage): 0.05% disodium EDTA, 2% glycerin, 0.5% panthenol, 2% butylene glycol, 0.03% hyaluronic acid, 0.01% sodium hyaluronate, 2% EMULIUM MELLIFERA raw material, 2% squalane, 2% caprylic / capric triglyceride, 2% dimethicone, 0.5% compound 7b, 0.9% Simulgel 305 raw material, 0.8% SPECTRASTARPHL raw material, 1% NACARE Cerasome III (ceramide), 6% raw material, and the balance was water.
[0226] Comparative Preparation Example 1: A skin lotion used as a comparative example was prepared in the same manner as Preparation Example 1 except that Compound 7b was not included.
[0227] Test Example 1: Determination of the inhibitory activity of compounds on PDE4
[0228] The phosphodiesterase proximity assay (SPA) was used to determine the inhibitory activity of the compounds on PDE4. 3 H]-cAMP hydrolysis products [ 3 The effect of the compound on the hydrolysis activity of PDE4 was identified by the scintillation light stimulated by the binding of [H]-AMP to scintillation beads under the chelation of metal ions. The volume of the entire enzymatic reaction system was 125 μL, and the protein solution with a concentration of 0.01-0.06 ng / μL was prepared using an assay buffer (50 mM Tris pH 7.5, 8.3 mM MgCl2, 1.7 mM EGTA).
[0229] Specific experimental steps: Use SPA reaction buffer to prepare protein solution (working concentration is 0.01-0.06ng / μL) and configure the corresponding concentration of compound. During the test, the reaction system of each well is 125μL, and 10μL of compound solution (the final concentration of DMSO does not exceed 1%), 80μL of the above protein solution and 10μL [ 3 H]-cAMP (final concentration 0.005 μCi / μL). After incubation at 30°C for 10 minutes, 25 μL of phosphodiesterase SPA scintillation beads were added to terminate the reaction. The reaction was allowed to stand at room temperature for 20 minutes, and luminescence was measured using a liquid scintillation counter MicroBeta2. All experimental data were analyzed using GraphPad Prism version 8.0 (GraphPad Inc.). The results are shown in Table 2.
[0230] Table 2. Inhibition rate of PDE4 by compounds at different concentrations
[0231]
[0232]
[0233]
[0234]
[0235] Description: N / A: No inhibition; *: 1-25%; **: 26-50%; ***: 51-75%; ****: 76-100%
[0236] As can be seen from the above table, except for compounds 7a-2, 8a, 9a, 12a, and 18, the other compounds have significant inhibitory activity against PDE4 at a concentration of 10 μM; at a concentration of 1 μM, compounds 6a, 6b, 7b, 13, 15, and 7b-1 still have significant inhibitory activity against PDE4; and then the concentration-dependent activity test of compound 7b-1 on the inhibition of PDE4 activity was carried out, and the results are as follows Figure 1 It was found that compound 7b-1 had the strongest PDE4 inhibitory activity (IC 50 =0.19 μM), and was superior to the positive compound crisaborole (IC 50 =0.49 μM).
[0237] Test Example 2: Determination of the inhibitory activity of compound 7b-1 on TNF-α secretion in PBMC
[0238] The experiment used enzyme linked immunosorbent assay (ELISA) to test the inhibitory activity of the compound on the secretion of inflammatory factor TNF-α in human peripheral blood mononuclear cells (hPBMC). The inhibitory activity of compound 7b-1 on PDE4 at the cellular level was evaluated by detecting the inhibitory activity of the compound on the production of TNF-α in the hPBMC inflammatory cell model.
[0239] Specific experimental steps: hPBMC cell pellets were collected by centrifugation at 6 × 10 6 / mL was resuspended in RPMI1640 culture medium containing 10% FBS, and added to a 96-well plate at 150μL / well, and incubated in a 37°C, 5% CO2 incubator for 2-3 hours. 25μL of gradient concentration compound solution or cell culture medium was added to each well, ensuring that the final concentration of DMSO in each well did not exceed 0.2%, and continued to incubate in a 37°C, 5% CO2 incubator for 1-1.5 hours. Finally, 25μL of LPS (final concentration of 1μg / mL) or cell culture medium was added, and incubated at 37°C, 5% CO2 for 24 hours to stimulate the cells to produce TNF-α. The cell supernatant was collected, and the inhibitory activity of the compound on TNF-α release was determined using an ELISA kit. The experimental data were analyzed using GraphPad Prism version 8.0 (GraphPad Inc.). The results are shown in Figure 2 As shown, the EC of compound 7b-1 on the inhibitory activity of TNF-α production in hPBMC inflammatory cell model 50 The value is 0.32μM.
[0240] Test Example 3: Therapeutic effect of compound 7b-1 on imiquimod-stimulated psoriasis in mice
[0241] The psoriasis model was established by applying imiquimod to the back skin of female BALB / c mice, and the mouse model was scored according to the Psoriasis Lesion Area and Severity Index (PASI). The mice were randomly divided into 5 groups, 8 in each group (normal group, model group, low-dose group and high-dose group). Before the experiment, 100uL of blood was collected from each animal, centrifuged twice at 4°C 4000g, and serum was obtained. On days 1-5, after the mice were depilated, imiquimod (60 mg per day) was applied to the back skin for modeling, and applied once a day. On days 6-15, the drug was applied for treatment, and the application method (calculated according to 10 days of drug treatment) was as follows: imiquimod was applied at about 9:00 am every day, and the residual imiquimod on the back was wiped off at about 15:00 pm, and then the treatment drug was applied (model group, low-dose group: 0.3% compound 7b-1, high-dose group: 2% compound 7b-1, both 60 mg per day).
[0242] From the beginning of modeling to the end of the experiment, the skin on the back of the animals was photographed every morning, and the mouse model was scored and recorded according to the Psoriasis Lesion Area and Severity Index (PASI):
[0243] ① Erythema. 0 means no erythema, 1 means light red erythema, 2 means red erythema, 3 means dark red erythema.
[0244] Red, 4 points for very deep erythema;
[0245] ② Scales. 0 means no scales on the surface, 1 means scales on some lesions, 2 means most lesions are covered with scales, 3 means almost all lesions are covered with scales in layers, 4 means the lesions are covered with scales in layers,
[0246] All covered with scales;
[0247] ③ Thickness. 0 points means the lesion is flush with the normal skin, 1 point means the lesion is slightly higher than the normal skin surface, 2 points means the lesion is moderately raised, 3 points means the lesion is thick and obviously raised, and 4 points means the lesion is highly thick and obviously raised.
[0248] On the 15th day, 10 days after treatment, 100 μL of blood was collected from each animal and centrifuged twice at 40,000 g to obtain serum. Afterwards, the mice were euthanized and the back skin (skin at the modeling and drug administration sites) was collected and preserved in 4% paraformaldehyde.
[0249] The experimental results are as follows Figure 3 As shown, compared with the model group, the skin lesions in the high-dose group were alleviated in terms of scaling, erythema and PASI score from the 5th day (P<0.05); the skin lesions in the low-dose group were alleviated in terms of scaling and PASI score from the 6th day (P<0.05).
[0250] Test Example 4: Therapeutic effect of compound 7b-1 on atopic dermatitis in mice stimulated by 2,4-dinitrochlorobenzene (DNCB)
[0251] The effect of compound 7b-1 on DNCB-stimulated atopic dermatitis in mice was tested. Female Balb / C mice were used as experimental subjects and randomly divided into 4 groups, namely, blank group, model group, 0.3% 7b-1 group and positive drug crisaborole group (containing 2% crisaborole); the mice were depilated before the experiment, 5% DNCB was applied to the back skin of the mice on the first day for sensitization, and drugs were applied to the back of the mice on the 2nd to 8th days (positive drug: 2% crisaborole, 7b-1 group: 0.3% 7b-1, both 50 mg per day), and 1% DNCB was applied on the 9th day to stimulate allergic reactions, and the allergic reaction of the back skin of the mice was observed 54 hours later to evaluate the degree of dermatitis. As shown in Table 3, the four categories of symptoms (erythema or hemorrhage, edema or papules, scaling or dryness, epidermal exfoliation or scratches) on the back skin of mice were evaluated, with scores of 0 (none), 1 (mild), 2 (moderate), and 3 (severe). Dermatitis symptoms between two degrees were scored as 0.5 points. The final score of dermatitis on the back of mice was the sum of the four categories of symptoms.
[0252] Table 3. Atopic dermatitis skin lesion scoring table
[0253]
[0254] The experimental results are as follows Figure 4 As shown, compared with the model group, 7b-1 had significant differences in skin lesion and scaling scores (P<0.001), which were comparable to the positive drug crisaborole group.
[0255] Test Example 5: Test on improving skin sensitivity
[0256] Apply 50 μL of 10% (w / w) lactic acid aqueous solution to the nasolabial groove on either side, and apply normal saline to the other side. Ask the subject about their subjective symptoms at 30 seconds, 2.5 minutes, and 5 minutes, and record them. Score according to the 4-point method (0 for no tingling, 1 for mild tingling, 2 for moderate tingling, and 3 for severe tingling). Subtract the total scores of the two sides (10% lactic acid side and normal saline control side). Those with a difference of ≥3 points are considered positive for lactic acid tingling reaction. Select the subjects with positive lactic acid tingling reaction as qualified subjects for the next test.
[0257] Sample test: The above-mentioned subjects with positive lactic acid stinging reaction were randomly divided into 14 groups (20-50 years old, half male and half female), 5 people in each group, of which the control group did not use any product, and the test group used the embodiment or comparative example product shown in Table 4, one stick at a time, once a day. The test period was 28 days, and the lactic acid stinging test was performed on the first day (D0), the fourteenth day (D14) and the twenty-eighth day (D28) of the selected test, and the skin moisture content was tested by a skin moisture meter. The experimental results are shown in Tables 4 and 5.
[0258] Table 4 Average scores of lactic acid stinging test for each group of subjects
[0259] D0 D14 D28 Preparation Example 1 7.24±0.55 4.44±0.32 3.22±0.26 Preparation Example 2 7.42±0.24 5.29±0.73 4.07±0.43 Preparation Example 3 7.37±0.18 6.38±0.16 4.87±0.22 Comparative Preparation Example 1 7.19±1.20 7.32±0.67 7.61±1.48
[0260] From the results in Table 4, it can be seen that the lactic acid stinging test scores of the test groups of the preparation samples decreased, indicating that the skin sensitivity of the subjects using the samples of the preparations decreased and the skin barrier was better. However, after the comparison preparation lacked compound 7b, the skin sensitivity score did not decrease, indicating that after the lack of compound 7b, the repair performance of the lotion was significantly reduced.
[0261] Table 5 Average skin moisture content of subjects in each group
[0262] D0 D14 D28 Preparation Example 1 51.34±0.42 58.72±0.08 64.23±0.27 Preparation Example 2 50.28±0.84 56.59±0.36 61.92±0.43 Preparation Example 3 52.07±0.54 55.82±1.15 58.81±0.71 Comparative Preparation Example 1 49.77±0.96 50.06±1.27 48.63±1.13
[0263] As shown in Table 5, the skin moisture content of the subjects in each preparation example increased, which corresponds to the lactic acid stinging score, indicating that the skin barrier function of the subjects in each embodiment was improved, the skin condition was improved, and the water retention capacity was enhanced. However, after the comparison preparation example lacked compound 7b, the skin sensitivity score did not decrease, indicating that after the lack of compound 7b, the repair performance of the lotion was significantly reduced.
[0264] The results in Tables 4 and 5 above demonstrate that cosmetics containing compound 7b can significantly improve skin sensitivity.
[0265] Summarize
[0266] Experiments have shown that the compound of formula I described in the present invention can significantly inhibit the activity of PDE4 enzyme, increase the cAMP content in cells, and significantly inhibit the secretion of inflammatory factor TNF-α in human peripheral blood mononuclear cells. The IC of representative compound 7b-1 for inhibiting PDE4 at the enzyme level is 50 =0.19 μM, 7b-1 inhibited the secretion of inflammatory factor TNF-α in human peripheral blood mononuclear cells at the cellular level. 50 =0.32 μM. In the pharmacodynamics experiment, the representative compound 7b-1 can effectively reduce the skin damage of imiquimod-induced psoriasis mice and DNCB-stimulated atopic dermatitis mice, and has a clear therapeutic effect on psoriasis and atopic dermatitis. Therefore, the compound of formula I is expected to be used as an active ingredient in the preparation of drugs for the prevention and treatment of phosphodiesterase 4-related diseases, and has a wide range of application prospects in drugs and personal care products.
[0267] Finally, it is necessary to explain here that the above embodiments are only used to further illustrate the technical solution of the present invention in detail and cannot be understood as limiting the scope of protection of the present invention. Some non-essential improvements and adjustments made by technicians in this field based on the above content of the present invention all fall within the scope of protection of the present invention.
Claims
1. A compound represented by the following formula I, its stereoisomer, precursor compound, deuterated substance, or pharmaceutically acceptable ester: In formula I, Z is O, NH or S; R1 is selected from H, unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, unsubstituted or halogen-substituted benzyl; R2 and R3 are each independently selected from unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, and unsubstituted or halogen-substituted benzyl; One of R6 and R7 is H, and the other is in, represents a single bond or a double bond; R4 and R5 are each independently selected from R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, In the above substituent options Indicates the key connection position, Provided that the compound of formula I does not include compound 2. The compound of formula I according to claim 1, its stereoisomer, precursor compound, deuterated substance, or pharmaceutically acceptable ester, which has the structure shown in the following formula I-1: In formula I-1, each substituent is as defined in claim 1.
3. A compound of formula I according to claim 1, its stereoisomer, precursor compound, deuterated substance, or pharmaceutically acceptable ester, in, In Formula I, Z is O; R1 is selected from H, C1-C6 alkyl; R2 and R3 are each independently C1-C6 alkyl; R6 is H, and R7 is Or R6 is and R7 is H, wherein, represents a single bond or a double bond; R4 and R5 are each independently selected from R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, In the above substituent options Indicates the key connection location.
4. A compound of formula I according to claim 1, its stereoisomer, precursor compound, deuterated substance, or pharmaceutically acceptable ester, in, In Formula I, Z is O; R1 is H or methyl; R2 and R3 are both methyl, or R2 and R3 are both ethyl; R6 is H, and R7 is Or R7 is H, and R6 is in, represents a single bond or a double bond; R4 and R5 are each independently selected from R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, In the above substituent options Indicates the key connection location.
5. A compound selected from the following structures:
6. A pharmaceutical composition comprising a compound of formula I as claimed in any one of claims 1 to 5, a deuterated substance thereof, or a pharmaceutically acceptable ester, and a pharmaceutically acceptable excipient.
7. Use of a compound of formula I, a deuterated substance thereof, or a pharmaceutically acceptable ester thereof, or a pharmaceutical composition comprising the same, in the preparation of a medicament for treating a disease mediated by upregulation of phosphodiesterase 4, a PDE4 inhibitor, or a cosmetic for improving skin sensitivity: In formula I, Z is O, NH or S; R1 is selected from H, unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, unsubstituted or halogen-substituted benzyl; R2 and R3 are each independently selected from unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, and unsubstituted or halogen-substituted benzyl; One of R6 and R7 is H, and the other is in, represents a single bond or a double bond; R4 and R5 are each independently selected from Wherein, R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, R 10 is a C1-C6 alkyl group, In the above substituent options Indicates the key connection location.
8. The use according to claim 7, wherein the compound of formula I is selected from the following:
9. The use according to claim 7 or 8, wherein Such diseases include: diseases involving inflammation, such as asthma, COPD, and pulmonary fibrosis; Allergic disease states, such as atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, chronic glomerulonephritis, endotoxic shock, cystic fibrosis, arterial restenosis, atherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, diabetes, pneumoconiosis, toxic and allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, pruritus of the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular and generalized pyoderma, intrinsic or extrinsic acne, rosacea, Beghet's disease, Henoch-Schönlein purpura nephritis, inflammatory bowel disease, leukemia, multiple sclerosis, gastrointestinal diseases, autoimmune diseases; Cardiovascular diseases, such as arrhythmia, heart failure, idiopathic dilated cardiomyopathy, acute myocardial infarction, myocardial ischemia-reperfusion injury, and ischemic pulmonary hypertension; Neurological and psychiatric disorders, such as Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, depression, stroke, and spinal cord injury, vascular dementia, fragile X syndrome; and Malignancies, including central nervous system tumors, hematological malignancies, lung cancer, liver cancer, oral cancer, breast cancer, colon cancer, stomach cancer, skin cancer, prostate cancer, head and neck cancer, bladder cancer, and pancreatic cancer.
10. The use according to claim 7 or 8, wherein The disease is psoriasis or atopic dermatitis.
Citation Information
Cited By
9apos; 9apos; carrying out apos; carrying out apos; application of salvianolic acid B monomethyl ester in preparation of medicine for preventing and / or treating atrial fibrillation
CN121445730A
